Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry

Developmental Cell

Volumn 19, Issue 5, 2010, Pages 698-711

  Berdasco, María ^a   Esteller, Manel ^a,b  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; MICRORNA;

CARCINOGENESIS; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE CONTROL; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; X CHROMOSOME INACTIVATION;

ANIMALS; CELL DIFFERENTIATION; DNA METHYLATION; EMBRYONIC DEVELOPMENT; EPIGENESIS, GENETIC; EPIGENOMICS; GENOMIC IMPRINTING; GENOMIC INSTABILITY; HISTONES; HUMANS; MICRORNAS; NEOPLASMS; X CHROMOSOME INACTIVATION;

EID: 78149478781     PISSN: 15345807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.devcel.2010.10.005     Document Type: Review

References (181)

1. Akimzhanov A.M., Yang X.O., Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J. Biol. Chem. 2007, 282:5969-5972.
2. Allegrucci C., Thurston A., Lucas E., Young L. Epigenetics and the germline. Reproduction 2005, 129:137-149.
3. Almeida L.G., Sakabe N.J., deOliveira A.R., Silva M.C., Mundstein A.S., Cohen T., Chen Y.T., Chua R., Gurung S., Gnjatic S., et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 2009, 37(Database issue):D816-D819.
4. Altuvia Y., Landgraf P., Lithwick G., Elefant N., Pfeffer S., Aravin A., Brownstein M.J., Tuschl T., Margalit H. Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 2005, 33:2697-2706.
5. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
6. Angrand P.O., Apiou F., Stewart A.F., Dutrillaux B., Losson R., Chambon P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001, 74:79-88.
7. Antequera F. Structure, function and evolution of CpG island promoters. Cell. Mol. Life Sci. 2003, 60:1647-1658.
8. Azuara V., Perry P., Sauer S., Spivakov M., Jørgensen H.F., John R.M., Gouti M., Casanova M., Warnes G., Merkenschlager M., Fisher A.G. Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 2006, 8:532-538.
9. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
10. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
11. Benbrahim-Tallaa L., Waterland R.A., Styblo M., Achanzar W.E., Webber M.M., Waalkes M.P. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol. Appl. Pharmacol. 2005, 206:288-298.
12. Berdasco M., Ropero S., Setien F., Fraga M.F., Lapunzina P., Losson R., Alaminos M., Cheung N.K., Rahman N., Esteller M. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl. Acad. Sci. USA 2009, 106:21830-21835.
13. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., Fry B., Meissner A., Wernig M., Plath K., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
14. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669-681.
15. Bettstetter M., Woenckhaus M., Wild P.J., Rümmele P., Blaszyk H., Hartmann A., Hofstädter F., Dietmaier W. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J. Pathol. 2005, 205:606-614.
16. Bjornsson H.T., Brown L.J., Fallin M.D., Rongione M.A., Bibikova M., Wickham E., Fan J.B., Feinberg A.P. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J. Natl. Cancer Inst. 2007, 99:1270-1273.
17. Boltze C., Schneider-Stock R., Quednow C., Hinze R., Mawrin C., Hribaschek A., Roessner A., Hoang-Vu C. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int. J. Mol. Med. 2003, 12:479-484.
18. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
19. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
20. Bueno M.J., Pérez de Castro I., Gómez de Cedrón M., Santos J., Calin G.A., Cigudosa J.C., Croce C.M., Fernández-Piqueras J., Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13:496-506.
21. Bulger M., Schübeler D., Bender M.A., Hamilton J., Farrell C.M., Hardison R.C., Groudine M. A complex chromatin landscape revealed by patterns of nuclease sensitivity and histone modification within the mouse beta-globin locus. Mol. Cell. Biol. 2003, 23:5234-5244.
22. Caiafa P., Zampieri M. DNA methylation and chromatin structure: the puzzling CpG islands. J. Cell. Biochem. 2005, 94:257-265.
23. Canaani E., Nakamura T., Rozovskaia T., Smith S.T., Mori T., Croce C.M., Mazo A. ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia. Br. J. Cancer 2004, 90:756-760.
24. Cerveira N., Correia C., Dória S., Bizarro S., Rocha P., Gomes P., Torres L., Norton L., Borges B.S., Castedo S., Teixeira M.R. Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia 2003, 17:2244-2247.
25. Chadwick B.P., Willard H.F. Chromatin of the Barr body: histone and non-histone proteins associated with or excluded from the inactive X chromosome. Hum. Mol. Genet. 2003, 12:2167-2178.
26. Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D., Pébusque M.J. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 2000, 28:138-144.
27. Chang H.H., Hemberg M., Barahona M., Ingber D.E., Huang S. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 2008, 453:544-547.
28. Choi S.C., Yoon J., Shim W.J., Ro Y.M., Lim D.S. 5-azacytidine induces cardiac differentiation of P19 embryonic stem cells. Exp. Mol. Med. 2004, 36:515-523.
29. Cloos P.A., Christensen J., Agger K., Maiolica A., Rappsilber J., Antal T., Hansen K.H., Helin K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006, 442:307-311.
30. Costello J.F., Plass C. Methylation matters. J. Med. Genet. 2001, 38:285-303.
31. Costello J.F., Frühwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomäki P., Lang J.C., et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24:132-138.
32. Cuddapah S., Barski A., Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr. Opin. Immunol. 2010, 22:341-347.
33. Cui K., Zang C., Roh T.Y., Schones D.E., Childs R.W., Peng W., Zhao K. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell 2009, 4:80-93.
34. Datta J., Kutay H., Nasser M.W., Nuovo G.J., Wang B., Majumder S., Liu C.G., Volinia S., Croce C.M., Schmittgen T.D., et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008, 68:5049-5058.
35. De Smet C., Lurquin C., Lethé B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 1999, 19:7327-7335.
36. De Smet C., Loriot A., Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol. Cell. Biol. 2004, 24:4781-4790.
37. Deng S., Calin G.A., Croce C.M., Coukos G., Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008, 7:2643-2646.
38. Dokun O.Y., Florl A.R., Seifert H.H., Wolff I., Schulz W.A. Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer. Int. J. Cancer 2008, 123:2798-2807.
39. Dolinoy D.C., Weidman J.R., Jirtle R.L. Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod. Toxicol. 2007, 23:297-307.
40. Du Y., Carling T., Fang W., Piao Z., Sheu J.C., Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res. 2001, 61:8094-8099.
41. Eckhardt F., Lewin J., Cortese R., Rakyan V.K., Attwood J., Burger M., Burton J., Cox T.V., Davies R., Down T.A., et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 2006, 38:1378-1385.
42. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
43. Ehrich M., Turner J., Gibbs P., Lipton L., Giovanneti M., Cantor C., van den Boom D. Cytosine methylation profiling of cancer cell lines. Proc. Natl. Acad. Sci. USA 2008, 105:4844-4849.
44. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 2005, 17:55-60.
45. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 2007, 8:286-298.
46. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
47. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
48. Esteller M., Fraga M.F., Guo M., Garcia-Foncillas J., Hedenfalk I., Godwin A.K., Trojan J., Vaurs-Barrière C., Bignon Y.J., Ramus S., et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum. Mol. Genet. 2001, 10:3001-3007.
49. Fan T., Schmidtmann A., Xi S., Briones V., Zhu H., Suh H.C., Gooya J., Keller J.R., Xu H., Roayaei J., et al. DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development. Epigenetics 2008, 3:134-142.
50. Feil R., Berger F. Convergent evolution of genomic imprinting in plants and mammals. Trends Genet. 2007, 23:192-199.
51. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
52. Ferri A.L., Cavallaro M., Braida D., Di Cristofano A., Canta A., Vezzani A., Ottolenghi S., Pandolfi P.P., Sala M., DeBiasi S., Nicolis S.K. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 2004, 131:3805-3819.
53. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van Putten W., Skrabanek L., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
54. Fiskus W., Wang Y., Joshi R., Rao R., Yang Y., Chen J., Kolhe R., Balusu R., Eaton K., Lee P., et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 2008, 14:6106-6115.
55. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., Heine-Suñer D., Cigudosa J.C., Urioste M., Benitez J., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl. Acad. Sci. USA 2005, 102:10604-10609.
56. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
57. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
58. Futscher B.W., Oshiro M.M., Wozniak R.J., Holtan N., Hanigan C.L., Duan H., Domann F.E. Role for DNA methylation in the control of cell type specific maspin expression. Nat. Genet. 2002, 31:175-179.
59. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
60. Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K., Chin S.F., Daigo Y., Russell P., Wilson A., Sowter H.M., et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 2000, 24:300-303.
61. Goelz S.E., Vogelstein B., Hamilton S.R., Feinberg A.P. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190.
62. Grady W.M., Parkin R.K., Mitchell P.S., Lee J.H., Kim Y.H., Tsuchiya K.D., Washington M.K., Paraskeva C., Willson J.K., Kaz A.M., et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008, 27:3880-3888.
63. Greger V., Passarge E., Höpping W., Messmer E., Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 1989, 83:155-158.
64. Grunau C., Hindermann W., Rosenthal A. Large-scale methylation analysis of human genomic DNA reveals tissue-specific differences between the methylation profiles of genes and pseudogenes. Hum. Mol. Genet. 2000, 9:2651-2663.
65. Grunau C., Sanchez C., Ehrlich M., van der Bruggen P., Hindermann W., Rodriguez C., Krieger S., Dubeau L., Fiala E., De Sario A. Frequent DNA hypomethylation of human juxtacentromeric BAGE loci in cancer. Genes Chromosomes Cancer 2005, 43:11-24.
66. Gupta A., Godwin A.K., Vanderveer L., Lu A., Liu J. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003, 63:664-673.
67. Hanigan C.L., Van Engeland M., De Bruine A.P., Wouters K.A., Weijenberg M.P., Eshleman J.R., Herman J.G. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008, 135:1654-1664. e2.
68. Hattori N., Nishino K., Ko Y.G., Hattori N., Ohgane J., Tanaka S., Shiota K. Epigenetic control of mouse Oct-4 gene expression in embryonic stem cells and trophoblast stem cells. J. Biol. Chem. 2004, 279:17063-17069.
69. Hattori N., Imao Y., Nishino K., Hattori N., Ohgane J., Yagi S., Tanaka S., Shiota K. Epigenetic regulation of Nanog gene in embryonic stem and trophoblast stem cells. Genes Cells 2007, 12:387-396.
70. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A., Nakamura Y., Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer. 2010, Published online March 23, 2010. 10.1002/ijc.25349.
71. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
72. Henckel A., Nakabayashi K., Sanz L.A., Feil R., Hata K., Arnaud P. Histone methylation is mechanistically linked to DNA methylation at imprinting control regions in mammals. Hum. Mol. Genet. 2009, 18:3375-3383.
73. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
74. Herranz M., Martín-Caballero J., Fraga M.F., Ruiz-Cabello J., Flores J.M., Desco M., Marquez V., Esteller M. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 2006, 107:1174-1177.
75. Houshdaran S., Hawley S., Palmer C., Campan M., Olsen M.N., Ventura A.P., Knudsen B.S., Drescher C.W., Urban N.D., Brown P.O., Laird P.W. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE 2010, 5:e9359.
76. Huang Y.W., Liu J.C., Deatherage D.E., Luo J., Mutch D.G., Goodfellow P.J., Miller D.S., Huang T.H. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res. 2009, 69:9038-9046.
77. Huangfu D., Maehr R., Guo W., Eijkelenboom A., Snitow M., Chen A.E., Melton D.A. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat. Biotechnol. 2008, 26:795-797.
78. Ida K., Kitabayashi I., Taki T., Taniwaki M., Noro K., Yamamoto M., Ohki M., Hayashi Y. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 1997, 90:4699-4704.
79. Illingworth R., Kerr A., Desousa D., Jørgensen H., Ellis P., Stalker J., Jackson D., Clee C., Plumb R., Rogers J., et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol. 2008, 6:e22.
80. Imamura T., Ohgane J., Ito S., Ogawa T., Hattori N., Tanaka S., Shiota K. CpG island of rat sphingosine kinase-1 gene: tissue-dependent DNA methylation status and multiple alternative first exons. Genomics 2001, 76:117-125.
81. Ionov Y., Matsui S., Cowell J.K. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc. Natl. Acad. Sci. USA 2004, 101:1273-1278.
82. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
83. Issa J.P., Ahuja N., Toyota M., Bronner M.P., Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001, 61:3573-3577.
84. Italiano A., Attias R., Aurias A., Pérot G., Burel-Vandenbos F., Otto J., Venissac N., Pedeutour F. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet. Cytogenet. 2006, 167:122-130.
85. Jacinto F.V., Ballestar E., Esteller M. Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation. Oncogene 2009, 28:4212-4224.
86. Jaju R.J., Fidler C., Haas O.A., Strickson A.J., Watkins F., Clark K., Cross N.C., Cheng J.F., Aplan P.D., Kearney L., et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001, 98:1264-1267.
87. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
88. Kacem S., Feil R. Chromatin mechanisms in genomic imprinting. Mamm. Genome 2009, 20:544-556.
89. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., Solleder G., Bastian P.J., Ellinger J., Metzger E., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66:11341-11347.
90. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.L., Leighton J.K., Patel H., Rahman A., Sridhara R., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 2005, 11:3604-3608. FDA.
91. Karpf A.R., Matsui S. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res. 2005, 65:8635-8639.
92. Khalkhali-Ellis Z. Maspin: the new frontier. Clin. Cancer Res. 2006, 12:7279-7283.
93. Kiefer J.C. Epigenetics in development. Dev. Dyn. 2007, 236:1144-1156.
94. Kiefer C.M., Hou C., Little J.A., Dean A. Epigenetics of beta-globin gene regulation. Mutat. Res. 2008, 647:68-76.
95. Kishimoto M., Kohno T., Okudela K., Otsuka A., Sasaki H., Tanabe C., Sakiyama T., Hirama C., Kitabayashi I., Minna J.D., et al. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res. 2005, 11:512-519.
96. Komatsu S., Imoto I., Tsuda H., Kozaki K.I., Muramatsu T., Shimada Y., Aiko S., Yoshizumi Y., Ichikawa D., Otsuji E., Inazawa J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30:1139-1146.
97. Kondo Y., Kanai Y., Sakamoto M., Mizokami M., Ueda R., Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis-A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000, 32:970-979.
98. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
99. Kozaki K., Imoto I., Mogi S., Omura K., Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68:2094-2105.
100. Lehmann U., Hasemeier B., Christgen M., Müller M., Römermann D., Länger F., Kreipe H. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J. Pathol. 2008, 214:17-24.
101. Li H., Ma X., Wang J., Koontz J., Nucci M., Sklar J. Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc. Natl. Acad. Sci. USA 2007, 104:20001-20006.
102. Lindsey J.C., Lusher M.E., Strathdee G., Brown R., Gilbertson R.J., Bailey S., Ellison D.W., Clifford S.C. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int. J. Cancer 2006, 118:346-352.
103. Liu J., Casaccia P. Epigenetic regulation of oligodendrocyte identity. Trends Neurosci. 2010, 33:193-201.
104. Liu G., Bollig-Fischer A., Kreike B., van de Vijver M.J., Abrams J., Ethier S.P., Yang Z.Q. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009, 28:4491-4500.
105. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setién F., Casado S., Suarez-Gauthier A., Sanchez-Cespedes M., Git A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67:1424-1429.
106. Lujambio A., Calin G.A., Villanueva A., Ropero S., Sánchez-Céspedes M., Blanco D., Montuenga L.M., Rossi S., Nicoloso M.S., Faller W.J., et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl. Acad. Sci. USA 2008, 105:13556-13561.
107. Martinez R., Martin-Subero J.I., Rohde V., Kirsch M., Alaminos M., Fernandez A.F., Ropero S., Schackert G., Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4:255-264.
108. Mayer W., Niveleau A., Walter J., Fundele R., Haaf T. Demethylation of the zygotic paternal genome. Nature 2000, 403:501-502.
109. Melo S.A., Ropero S., Moutinho C., Aaltonen L.A., Yamamoto H., Calin G.A., Rossi S., Fernandez A.F., Carneiro F., Oliveira C., et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat. Genet. 2009, 41:365-370.
110. Miremadi A., Oestergaard M.Z., Pharoah P.D., Caldas C. Cancer genetics of epigenetic genes. Hum. Mol. Genet. 2007, 16(Spec No 1):R28-R49.
111. Mishra B.P., Ansari K.I., Mandal S.S. Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle. FEBS J. 2009, 276:1629-1640.
112. Mohn F., Weber M., Rebhan M., Roloff T.C., Richter J., Stadler M.B., Bibel M., Schübeler D. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol. Cell 2008, 30:755-766.
113. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
114. Murrell A., Ito Y., Verde G., Huddleston J., Woodfine K., Silengo M.C., Spreafico F., Perotti D., De Crescenzo A., Sparago A., Cerrato F., Riccio A. Distinct methylation changes at the IGF2-H19 locus in congenital growth disorders and cancer. PLoS ONE 2008, 3:e1849.
115. Ng E.K., Tsang W.P., Ng S.S., Jin H.C., Yu J., Li J.J., Röcken C., Ebert M.P., Kwok T.T., Sung J.J. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 2009, 101:699-706.
116. Niwa T., Tsukamoto T., Toyoda T., Mori A., Tanaka H., Maekita T., Ichinose M., Tatematsu M., Ushijima T. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010, 70:1430-1440.
117. Nomura T., Kimura M., Horii T., Morita S., Soejima H., Kudo S., Hatada I. MeCP2-dependent repression of an imprinted miR-184 released by depolarization. Hum. Mol. Genet. 2008, 17:1192-1199.
118. Noonan E.J., Place R.F., Pookot D., Basak S., Whitson J.M., Hirata H., Giardina C., Dahiya R. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28:1714-1724.
119. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Chen W., Daniel V.C., Yu W., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39:237-242.
120. Ohshima T., Suganuma T., Ikeda M. A novel mutation lacking the bromodomain of the transcriptional coactivator p300 in the SiHa cervical carcinoma cell line. Biochem. Biophys. Res. Commun. 2001, 281:569-575.
121. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
122. Orford K., Kharchenko P., Lai W., Dao M.C., Worhunsky D.J., Ferro A., Janzen V., Park P.J., Scadden D.T. Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Dev. Cell 2008, 14:798-809.
123. Ozdaĝ H., Batley S.J., Försti A., Iyer N.G., Daigo Y., Boutell J., Arends M.J., Ponder B.A., Kouzarides T., Caldas C. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br. J. Cancer 2002, 87:1162-1165.
124. Ozdaĝ H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., Veerakumarasivam A., Burtt G., Subkhankulova T., Arends M.J., et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7:90.
125. Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U., Billström R., Strömbeck B., Mitelman F., Johansson B. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum. Mol. Genet. 2001, 10:395-404.
126. Panagopoulos I., Isaksson M., Lindvall C., Hagemeijer A., Mitelman F., Johansson B. Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage-repair mechanism in the origin of the t(8;16)(p11;p13). Genes Chromosomes Cancer 2003, 36:90-98.
127. Panagopoulos I., Mertens F., Griffin C.A. An endometrial stromal sarcoma cell line with the JAZF1/PHF1 chimera. Cancer Genet. Cytogenet. 2008, 185:74-77.
128. Paz M.F., Avila S., Fraga M.F., Pollan M., Capella G., Peinado M.A., Sanchez-Cespedes M., Herman J.G., Esteller M. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 2002, 62:4519-4524.
129. Paz M.F., Fraga M.F., Avila S., Guo M., Pollan M., Herman J.G., Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003, 63:1114-1121.
130. Plath K., Fang J., Mlynarczyk-Evans S.K., Cao R., Worringer K.A., Wang H., de la Cruz C.C., Otte A.P., Panning B., Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science 2003, 300:131-135.
131. Poirier L.A., Vlasova T.I. The prospective role of abnormal methyl metabolism in cadmium toxicity. Environ. Health Perspect. 2002, 110(Suppl 5):793-795.
132. Qiu G., Fang J., He Y. 5′ CpG island methylation analysis identifies the MAGE-A1 and MAGE-A3 genes as potential markers of HCC. Clin. Biochem. 2006, 39:259-266.
133. Rauch T.A., Wu X., Zhong X., Riggs A.D., Pfeifer G.P. A human B cell methylome at 100-base pair resolution. Proc. Natl. Acad. Sci. USA 2009, 106:671-678.
134. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007, 447:425-432.
135. Reik W., Lewis A. Co-evolution of X-chromosome inactivation and imprinting in mammals. Nat. Rev. Genet. 2005, 6:403-410.
136. Reik W., Dean W., Walter J. Epigenetic reprogramming in mammalian development. Science 2001, 293:1089-1093.
137. Rideout W.M., Eggan K., Jaenisch R. Nuclear cloning and epigenetic reprogramming of the genome. Science 2001, 293:1093-1098.
138. Robert I., Aussems M., Keutgens A., Zhang X., Hennuy B., Viatour P., Vanstraelen G., Merville M.P., Chapelle J.P., de Leval L., et al. Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes. Oncogene 2009, 28:1626-1638.
139. Roh T.Y., Cuddapah S., Cui K., Zhao K. The genomic landscape of histone modifications in human T cells. Proc. Natl. Acad. Sci. USA 2006, 103:15782-15787.
140. Rokudai S., Aikawa Y., Tagata Y., Tsuchida N., Taya Y., Kitabayashi I. Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest. J. Biol. Chem. 2009, 284:237-244.
141. Ropero S., Fraga M.F., Ballestar E., Hamelin R., Yamamoto H., Boix-Chornet M., Caballero R., Alaminos M., Setien F., Paz M.F., et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38:566-569.
142. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
143. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am. J. Hum. Genet. 1991, 48:880-888.
144. Salnikow K., Costa M. Epigenetic mechanisms of nickel carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 2000, 19:307-318.
145. Sato N., Fukushima N., Matsubayashi H., Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004, 23:1531-1538.
146. Schilling E., Rehli M. Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics 2007, 90:314-323.
147. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39:232-236.
148. Schoenborn J.R., Dorschner M.O., Sekimata M., Santer D.M., Shnyreva M., Fitzpatrick D.R., Stamatoyannopoulos J.A., Stamatoyonnapoulos J.A., Wilson C.B. Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nat. Immunol. 2007, 8:732-742.
149. Schulz W.A. L1 retrotransposons in human cancers. J. Biomed. Biotechnol. 2006, 2006:83672.
150. Scuto A., Kirschbaum M., Kowolik C., Kretzner L., Juhasz A., Atadja P., Pullarkat V., Bhatia R., Forman S., Yen Y., Jove R. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008, 111:5093-5100.
151. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
152. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
153. She X., Rohl C.A., Castle J.C., Kulkarni A.V., Johnson J.M., Chen R. Definition, conservation and epigenetics of housekeeping and tissue-enriched genes. BMC Genomics 2009, 10:269.
154. Shen L., Kondo Y., Guo Y., Zhang J., Zhang L., Ahmed S., Shu J., Chen X., Waterland R.A., Issa J.P. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 2007, 3:2023-2036.
155. Shi Y., Desponts C., Do J.T., Hahm H.S., Schöler H.R., Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008, 3:568-574.
156. Shigeno K., Yoshida H., Pan L., Luo J.M., Fujisawa S., Naito K., Nakamura S., Shinjo K., Takeshita A., Ohno R., Ohnishi K. Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett. 2004, 213:11-20.
157. Silber J., Lim D.A., Petritsch C., Persson A.I., Maunakea A.K., Yu M., Vandenberg S.R., Ginzinger D.G., James C.D., Costello J.F., et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008, 6:14.
158. Silbergeld E.K., Waalkes M., Rice J.M. Lead as a carcinogen: experimental evidence and mechanisms of action. Am. J. Ind. Med. 2000, 38:316-323.
159. Song F., Smith J.F., Kimura M.T., Morrow A.D., Matsuyama T., Nagase H., Held W.A. Association of tissue-specific differentially methylated regions (TDMs) with differential gene expression. Proc. Natl. Acad. Sci. USA 2005, 102:3336-3341.
160. Strathdee G., Davies B.R., Vass J.K., Siddiqui N., Brown R. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis 2004, 25:693-701.
161. Strathdee G., Sim A., Soutar R., Holyoake T.L., Brown R. HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. Carcinogenesis 2007, 28:299-309.
162. Szulwach K.E., Li X., Smrt R.D., Li Y., Luo Y., Lin L., Santistevan N.J., Li W., Zhao X., Jin P. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J. Cell Biol. 2010, 189:127-141.
163. Tan Y.C., Chow V.T. Novel human HALR (MLL3) gene encodes a protein homologous to ALR and to ALL-1 involved in leukemia, and maps to chromosome 7q36 associated with leukemia and developmental defects. Cancer Detect. Prev. 2001, 25:454-469.
164. Toyota M., Suzuki H., Sasaki Y., Maruyama R., Imai K., Shinomura Y., Tokino T. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008, 68:4123-4132.
165. Tsai K.W., Kao H.W., Chen H.C., Chen S.J., Lin W.C. Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics 2009, 4:587-592.
166. Valley C.M., Pertz L.M., Balakumaran B.S., Willard H.F. Chromosome-wide, allele-specific analysis of the histone code on the human X chromosome. Hum. Mol. Genet. 2006, 15:2335-2347.
167. van Haaften G., Dalgliesh G.L., Davies H., Chen L., Bignell G., Greenman C., Edkins S., Hardy C., O'Meara S., Teague J., et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41:521-523.
168. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
169. Wang J., Weaver I.C., Gauthier-Fisher A., Wang H., He L., Yeomans J., Wondisford F., Kaplan D.R., Miller F.D. CBP histone acetyltransferase activity regulates embryonic neural differentiation in the normal and Rubinstein-Taybi syndrome brain. Dev. Cell 2010, 18:114-125.
170. Waterland R.A., Lin J.R., Smith C.A., Jirtle R.L. Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus. Hum. Mol. Genet. 2006, 15:705-716.
171. Weber M., Hellmann I., Stadler M.B., Ramos L., Pääbo S., Rebhan M., Schübeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 2007, 39:457-466.
172. Wei Y.D., Tepperman K., Huang M.Y., Sartor M.A., Puga A. Chromium inhibits transcription from polycyclic aromatic hydrocarbon-inducible promoters by blocking the release of histone deacetylase and preventing the binding of p300 to chromatin. J. Biol. Chem. 2004, 279:4110-4119.
173. Wei G., Wei L., Zhu J., Zang C., Hu-Li J., Yao Z., Cui K., Kanno Y., Roh T.Y., Watford W.T., et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009, 30:155-167.
174. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157-158.
175. Wu X., Rauch T.A., Zhong X., Bennett W.P., Latif F., Krex D., Pfeifer G.P. CpG island hypermethylation in human astrocytomas. Cancer Res. 2010, 70:2718-2727.
176. Wu Y., Alvarez M., Slamon D.J., Koeffler P., Vadgama J.V. Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer 2010, 10:32.
177. Xu G.L., Bestor T.H., Bourc'his D., Hsieh C.L., Tommerup N., Bugge M., Hulten M., Qu X., Russo J.J., Viegas-Péquignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 1999, 402:187-191.
178. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004, 32:959-976.
179. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
180. Zhou G.S., Zhang X.L., Wu J.P., Zhang R.P., Xiang L.X., Dai L.C., Shao J.Z. 5-Azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylation. Cytotechnology 2009, (Jun):26.
181. Zhu C., Qin Y.R., Xie D., Chua D.T., Fung J.M., Chen L., Fu L., Hu L., Guan X.Y. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene 2009, 28:2821-2828.